63 results
6-K
EX-99.4
IMCR
Immunocore Holdings plc
10 Aug 23
Current report (foreign)
8:28am
KIMMTRAK duration of therapy <3 mo All patients transitioned to reimbursement in Italy
KIMMTRAK: Looking ahead * Subject to reimbursement … expected 4Q Expansion in Italy Several additional launches expected in Europe* Reimbursement US REFUND1 Act: CMS 2024 proposed rule Germany
F-1/A
EX-10.18
IMCR
Immunocore Holdings plc
1 Feb 21
Registration statement (foreign) (amended)
6:21am
and the relevant Option Documents.
2.5 Expense Reimbursement.
(a) General. The Company will reimburse Executive for reasonable business expenses in accordance … with the Company’s standard expense reimbursement policy, subject to any applicable payroll withholdings and deductions (if any).
(b) Travel
10-K
2023 FY
EX-10.12
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Reimbursement.
(a) General. The Company will reimburse Executive for reasonable business expenses in accordance with the Company’s standard expense … reimbursement policy, subject to any applicable payroll withholdings and deductions (if any).
(b) Travel. Executive shall be entitled to reimbursement
10-K
2023 FY
EX-10.13
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
be subject to all of the terms and conditions of the Plan and the relevant Option Documents.
2.5 Expense Reimbursement.
(a) General. The Company … will reimburse Executive for reasonable business expenses in accordance with the Company’s standard expense reimbursement policy, subject to any applicable
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government and third-party payors and risks relating … , and the Caribbean.
Reimbursement
Coverage in the United States, Europe and other territories
Table of Contents
In the United States
DRS
t6zp jqdq3d57u
17 Nov 20
Draft registration statement
12:00am
20-F
mkb6 iajgys
25 Mar 21
Annual report (foreign)
7:01am
DRS/A
6yvegq3jx85s3cpf
19 Nov 20
Draft registration statement (amended)
12:00am
10-K
EX-97.1
058wrk6ve2a g4n2a5
28 Feb 24
Annual report
7:33am
6-K
EX-99.3
q86r1bgj7ebmx
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
jcqsj
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
F-1/A
30j36p39fj
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1/A
p92ta3q 0b3893vbr
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1
e2qyugcj7nxwat3q
15 Jan 21
Registration statement (foreign)
4:57pm
424B4
y28ul0
8 Feb 21
Prospectus supplement with pricing info
8:36am
6-K
EX-99.2
hz8 q9ttaew8m8n
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
mca00dr2ork8zze8jzc
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
F-1
EX-10.7
s0lc3ihc
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.6
0xqor apwcp9
22 Dec 20
Draft registration statement (amended)
12:00am